JOP20200195A1 - سترويدات وتركيبات نشطة عصبياً، واستخداماتها - Google Patents

سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Info

Publication number
JOP20200195A1
JOP20200195A1 JOP/2020/0195A JOP20200195A JOP20200195A1 JO P20200195 A1 JOP20200195 A1 JO P20200195A1 JO P20200195 A JOP20200195 A JO P20200195A JO P20200195 A1 JOP20200195 A1 JO P20200195A1
Authority
JO
Jordan
Prior art keywords
depression
tremor
compositions
neuroactive steroids
anxiety disorder
Prior art date
Application number
JOP/2020/0195A
Other languages
English (en)
Inventor
Jay Kanes Stephen
Colquhoun Helen
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of JOP20200195A1 publication Critical patent/JOP20200195A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بوصف طرق لعلاج الارتعاش، على سبيل المثال، الارتعاش الأساسي؛ الاكتئاب، على سبيل المثال، اكتئاب ما بعد الولادة؛ واضطراب القلق، تضم الطريقة إعطاء خاضعة من البشر تعاني من الارتعاش، على سبيل المثال، الارتعاش الأساسي؛ الاكتئاب، على سبيل المثال، اكتئاب ما بعد الولادة، اضطراب القلق سترويد أو تركيبة نشطة عصبيًا تضم سترويد نشط عصبيًا (على سبيل المثال، بريجنانولون، ألوبريجنانولون، ألفادالون، جاناكسولون، أو ألفاكسولون).
JOP/2020/0195A 2014-09-08 2014-09-08 سترويدات وتركيبات نشطة عصبياً، واستخداماتها JOP20200195A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047599P 2014-09-08 2014-09-08
US201562170596P 2015-06-03 2015-06-03
US201562213015P 2015-09-01 2015-09-01

Publications (1)

Publication Number Publication Date
JOP20200195A1 true JOP20200195A1 (ar) 2017-06-16

Family

ID=55459478

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0195A JOP20200195A1 (ar) 2014-09-08 2014-09-08 سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JOP/2015/0218A JO3667B1 (ar) 2014-09-08 2015-09-08 سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2015/0218A JO3667B1 (ar) 2014-09-08 2015-09-08 سترويدات وتركيبات نشطة عصبياً، واستخداماتها

Country Status (18)

Country Link
US (2) US20170348327A1 (ar)
EP (1) EP3191101A4 (ar)
JP (3) JP6837430B2 (ar)
KR (2) KR102491549B1 (ar)
CN (2) CN107106574A (ar)
AU (3) AU2015315333A1 (ar)
BR (1) BR112017004535A2 (ar)
CA (1) CA2960611A1 (ar)
CO (1) CO2017003396A2 (ar)
IL (2) IL285703B2 (ar)
JO (2) JOP20200195A1 (ar)
MX (2) MX2017003037A (ar)
PE (2) PE20170904A1 (ar)
PH (1) PH12017500427A1 (ar)
RU (2) RU2731000C2 (ar)
SG (2) SG11201701815SA (ar)
TW (3) TWI688389B (ar)
WO (1) WO2016040322A1 (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014008895A (es) 2012-01-23 2014-11-25 Sage Therapeutics Inc Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
CA2966962C (en) * 2014-11-06 2023-10-10 Ieso Digital Health Limited Computer-based system for providing psychological therapy
PL3224269T3 (pl) 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
US20160228454A1 (en) * 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
US20180311258A1 (en) 2015-04-10 2018-11-01 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2017066626A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
BR112019003637A2 (pt) 2016-08-23 2019-08-06 Sage Therapeutics Inc um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
CA3049954A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
AU2019256828A1 (en) * 2018-04-17 2020-12-03 M et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
TW202005653A (zh) * 2018-06-12 2020-02-01 美商賽吉醫療公司 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019377074A1 (en) * 2018-11-05 2021-05-13 Ovid Therapeutics Inc. Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
CN111281877A (zh) * 2018-11-22 2020-06-16 南京诺瑞特医药科技有限公司 神经活性类固醇的新制剂
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations
WO2021195297A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2024054875A2 (en) * 2022-09-07 2024-03-14 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CN1171114A (zh) * 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
EP1218003A4 (en) * 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CA2472184C (en) 2002-01-14 2011-04-19 David Mark Lucas Magnetically detectable latex articles
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2527019A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
EP1591455A1 (en) * 2004-04-29 2005-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Essential tremor diagnostic and treatment
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
ES2589139T3 (es) 2007-06-15 2016-11-10 Research Triangle Institute Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
WO2010107922A1 (en) * 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP4335505A3 (en) * 2012-11-30 2024-06-05 The Regents of The University of California Anticonvulsant activity of steroids
JP6542127B2 (ja) 2012-12-18 2019-07-10 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk

Also Published As

Publication number Publication date
JP2017526703A (ja) 2017-09-14
JO3667B1 (ar) 2020-08-27
TWI784261B (zh) 2022-11-21
CO2017003396A2 (es) 2017-08-31
TWI688389B (zh) 2020-03-21
IL285703B1 (en) 2023-11-01
BR112017004535A2 (pt) 2018-07-03
KR20230015518A (ko) 2023-01-31
JP2022113879A (ja) 2022-08-04
JP2020059760A (ja) 2020-04-16
KR102491549B1 (ko) 2023-01-20
CN117679426A (zh) 2024-03-12
SG11201701815SA (en) 2017-04-27
MX2020011537A (es) 2020-11-24
IL285703B2 (en) 2024-03-01
MX2017003037A (es) 2017-06-14
IL250942B (en) 2021-09-30
JP6837430B2 (ja) 2021-03-03
RU2731000C2 (ru) 2020-08-26
PH12017500427A1 (en) 2017-07-31
CA2960611A1 (en) 2016-03-17
WO2016040322A1 (en) 2016-03-17
EP3191101A4 (en) 2018-04-11
RU2020127610A (ru) 2021-09-30
EP3191101A1 (en) 2017-07-19
RU2017111816A3 (ar) 2019-05-08
TW201625266A (zh) 2016-07-16
TW202329978A (zh) 2023-08-01
SG10202107866YA (en) 2021-08-30
AU2021202433C1 (en) 2024-01-25
AU2021202433A1 (en) 2021-05-13
PE20221050A1 (es) 2022-06-30
AU2023248120A1 (en) 2023-11-02
CN107106574A (zh) 2017-08-29
PE20170904A1 (es) 2017-07-12
AU2015315333A1 (en) 2017-03-23
RU2017111816A (ru) 2018-10-10
KR20170048567A (ko) 2017-05-08
AU2021202433B2 (en) 2023-07-13
IL285703A (en) 2021-09-30
TW202106306A (zh) 2021-02-16
IL250942A0 (en) 2017-04-30
US20170348327A1 (en) 2017-12-07
US20200253985A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2020011537A (es) Esteroides neuroactivos, composiciones y uso de los mismos.
PH12018501923A1 (en) Neuroactive steroids, compositions, and uses thereof
SG11202002085YA (en) Neuroactive steroids and their methods of use
SI2986624T1 (sl) 19-nor nevroaktivni steroidi za metode zdravljenja
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
EP3258939A4 (en) Neuroactive steroids, compositions, and uses thereof
EP3698656A4 (en) INHALATION SUBSTANCE TRAINING DEVICE, INHALATION SUBSTANCE TRAINING DEVICE CONTROL PROCESS AND PROGRAM
EP3149018A4 (en) Neuroactive steroids, compositions, and uses thereof
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EA201790884A1 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MX2021005489A (es) Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo.
MX2019001323A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
EP3310394A4 (en) NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
IL278906A (en) Compositions and methods for treating diseases or disorders related to steroid hormones
WO2018045078A3 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS
BR112018012347A2 (pt) método para a fabricação de corrente única de uma composição espumante, composição espumante e método para tratar um indivíduo tendo, ou em risco de ter, uma condição responsiva a corticosteroides
MY179214A (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate
ZA202100093B (en) Neuroactive steroids and methods of preparation
IN2014CH01890A (ar)